UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Outcome of t(4;14) in Multiple Myeloma – Princess Margaret Cancer Centre Experience Over the Last 10 Years

Clinical lymphoma, myeloma and leukemia, 2015-09, Vol.15, p.e145-e145

2015

Volltextzugriff (PDF)

A Retrospective Analysis at the Princess Margaret Cancer Centre of the Initial Therapy of AL Amyloidosis: CyBorD versus Other Regimens

Clinical lymphoma, myeloma and leukemia, 2015-09, Vol.15, p.e196-e197

2015

Volltextzugriff (PDF)

A Phase 1/2 Trial of the Insulin Growth Factor 1 Receptor (IGF-1R) inhibitor, Linsitinib in Combination with Bortezomib (BTZ) and Dexamethasone (Dex) for the Treatment of Relapsed/Refractory Multiple Myeloma (MM)

Clinical lymphoma, myeloma and leukemia, 2015-09, Vol.15, p.e286-e287

2015

Volltextzugriff (PDF)

9219 POSTER Combined Modality Therapy for Stage l-ll Diffuse Large B-cell Lymphoma Provides Excellent Local Control and Clinical Outcome in the Rituximab Era

European journal of cancer (1990), 2011, Vol.47, p.S644-S645

2011

Volltextzugriff (PDF)

Myeloma Canada Research Network (MCRN) 001 Trial with Intravenous (IV) Busulfan + Melphalan (BuMel) as Enhanced Conditioning, followed by Lenalidomide (Len) Maintenance in Newly Diagnosed Multiple Myeloma (MM) Patients (Pts): First Results of Minimal Residual Disease (MRD) and Hevylite(TM) Chain (HLC) Assays at Day 100 Post Autologous Stem Cell Transplant (ASCT)

Clinical lymphoma, myeloma and leukemia, 2015-09, Vol.15, p.e51-e52

2015

Volltextzugriff (PDF)

Noninvasive diagnosis of actionable mutations by deep sequencing of circulating cell free DNA (cfDNA) in multiple myeloma (MM)

Clinical lymphoma, myeloma and leukemia, 2015-09, Vol.15, p.e45-e46

2015

Volltextzugriff (PDF)

Positron Emission Tomography for Response Assessment of Lymphoma Patients Having Residual Abnormalities following Initial Treatment: The Impact on Clinical Management

International journal of radiation oncology, biology, physics, 2010, Vol.78 (3), p.S555-S555

2010

Volltextzugriff (PDF)

Studies on Volatile Characteristics of Middle Distillates and Their Interdependency

Petroleum science and technology, 2011-01, Vol.29 (22), p.2397-2406

2011

Volltextzugriff (PDF)

020 Best Practices and Performance Measures for Systemic Treatment Perscriber Order Entry Systems (STCPOE) in Chemotherapy Delivery

BMJ quality & safety, 2013-08, Vol.22 (Suppl 1), p.A18-A18

2013

Volltextzugriff (PDF)

Patterns of Relapse and Progression in Multiple Myeloma Patients Treated with Conventional and Novel Agent-Based Therapy: A Single Centre Experience

Blood, 2015-12, Vol.126 (23), p.5361-5361

2015

Volltextzugriff (PDF)

9236 Results of PX-171–003-A0, part 1 of an open-label, single-arm, phase 2 study of carfilzomib in patients with relapsed and refractory multiple myeloma

European journal of cancer supplements, 2009, Vol.7 (2), p.571-571

2009

Volltextzugriff (PDF)

9201 Tolerability profile of carfilzomib enables full-dose anti-tumor treatment for up to 12 months

European journal of cancer supplements, 2009, Vol.7 (2), p.560-560

2009

Volltextzugriff (PDF)

PROGNOSTIC FACTORS IN ELDERLY PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA ‐ A JOINT ANALYSIS OF TWO CLINICAL DATABASES

Hematological oncology, 2021-06, Vol.39 (S2)

2021

Volltextzugriff (PDF)

Clinical Characteristics and Treatment Outcomes in Patients Diagnosed with Primary Mediastinal Large B-Cell Lymphoma at Princess Margaret Cancer Centre from 1994-2012

BLOOD, 2014-12, Vol.124 (21), p.4447-4447

2014

Volltextzugriff (PDF)

ABSTRACT 327: BIOMARKERS IN MILD TRAUMATIC BRAIN INJURY

Pediatric critical care medicine, 2014-05, Vol.15, p.76-77

2014

Volltextzugriff (PDF)

PS1376 LENALIDOMIDE MAINTENANCE POSITIVELY IMPACTS OUTCOMES IN MULTIPLE MYELOMA WITHOUT NEGATIVE IMPACTS IN RELAPSE: AN ANALYSIS OF REAL WORLD DATA FROM THE MYELOMA CANADA RESEARCH NETWORK NATIONAL DATABASE

HemaSphere, 2019-06, Vol.3 (S1), p.629-630

2019

Volltextzugriff (PDF)

Synthesis and spectra of some new phthalein dyes

Dyes and pigments, 1996-09, Vol.32 (1), p.15-24

1996

Volltextzugriff (PDF)

Systemic Treatment Safety Symposium 2014: Oral Chemotherapy

Current oncology (Toronto), 2014-12, Vol.21 (6), p.794-800

2014

Volltextzugriff (PDF)

Results of an ongoing open-label, phase II study of carfilzomib in patients with relapsed and/or refractory multiple myeloma (R/R MM)

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.8000-8000

2010

Volltextzugriff (PDF)

PX-171–004, a multicenter phase II study of carfilzomib (CFZ) in patients with relapsed myeloma: An efficacy update

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.8537-8537

2009

Volltextzugriff (PDF)

The effect of carfilzomib (CFZ) in patients (Pts) with bortezomib (BTZ)-naive relapsed or refractory multiple myeloma (MM): Updated results from the PX-171-004 study

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.8026-8026

2011

Volltextzugriff (PDF)

PX-171-003-A1, an open-label, single-arm, phase (Ph) II study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (R/R MM): Long-term follow-up and subgroup analysis

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.8027-8027

2011

Volltextzugriff (PDF)

Efficacy of induction with cybord in newly diagnosed multiple myeloma

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.8517-8517

2008

Volltextzugriff (PDF)

A333 Phase I/II Trial of Cyclophosphamide, Prednisone, and Lenalidomide for Relapsed and Refractory MM

Clinical lymphoma & myeloma, 2009-02, Vol.9, p.S53-S53

2009

Volltextzugriff (PDF)

26 – 50 von 104

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(97)
Mit Volltextzugriff
(92)

Publikationsform

Sprache

Englisch
(104)

Erscheinungsjahr

n.n

Thema

Science & Technology
(50)
Life Sciences & Biomedicine
(40)
Humans
(31)
Female
(20)
Male
(17)
Adult
(15)
Hematology, Oncology And Palliative Medicine
(14)
Middle Aged
(14)
Biological And Medical Sciences
(11)
Oncology
(11)
Hematology
(10)
Aged
(9)
Biochemistry & Molecular Biology
(9)
Physical Sciences
(8)
Chemotherapy
(7)
Treatment Outcome
(7)
Lymphoma
(6)
Medical Sciences
(6)
Medicine
(6)
Medicine & Public Health
(6)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Outcome of t(4;14) in Multiple Myeloma – Princess Margaret Cancer Centre Experience Over the Last 10 Years

A Retrospective Analysis at the Princess Margaret Cancer Centre of the Initial Therapy of AL Amyloidosis: CyBorD versus Other Regimens

A Phase 1/2 Trial of the Insulin Growth Factor 1 Receptor (IGF-1R) inhibitor, Linsitinib in Combination with Bortezomib (BTZ) and Dexamethasone (Dex) for the Treatment of Relapsed/Refractory Multiple Myeloma (MM)

Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma

9219 POSTER Combined Modality Therapy for Stage l-ll Diffuse Large B-cell Lymphoma Provides Excellent Local Control and Clinical Outcome in the Rituximab Era

Noninvasive diagnosis of actionable mutations by deep sequencing of circulating cell free DNA (cfDNA) in multiple myeloma (MM)

Positron Emission Tomography for Response Assessment of Lymphoma Patients Having Residual Abnormalities following Initial Treatment: The Impact on Clinical Management

Studies on Volatile Characteristics of Middle Distillates and Their Interdependency

020 Best Practices and Performance Measures for Systemic Treatment Perscriber Order Entry Systems (STCPOE) in Chemotherapy Delivery

Patterns of Relapse and Progression in Multiple Myeloma Patients Treated with Conventional and Novel Agent-Based Therapy: A Single Centre Experience

9236 Results of PX-171–003-A0, part 1 of an open-label, single-arm, phase 2 study of carfilzomib in patients with relapsed and refractory multiple myeloma

9201 Tolerability profile of carfilzomib enables full-dose anti-tumor treatment for up to 12 months

PROGNOSTIC FACTORS IN ELDERLY PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA ‐ A JOINT ANALYSIS OF TWO CLINICAL DATABASES

Clinical Characteristics and Treatment Outcomes in Patients Diagnosed with Primary Mediastinal Large B-Cell Lymphoma at Princess Margaret Cancer Centre from 1994-2012

ABSTRACT 327: BIOMARKERS IN MILD TRAUMATIC BRAIN INJURY

PS1376 LENALIDOMIDE MAINTENANCE POSITIVELY IMPACTS OUTCOMES IN MULTIPLE MYELOMA WITHOUT NEGATIVE IMPACTS IN RELAPSE: AN ANALYSIS OF REAL WORLD DATA FROM THE MYELOMA CANADA RESEARCH NETWORK NATIONAL DATABASE

Synthesis and spectra of some new phthalein dyes

Systemic Treatment Safety Symposium 2014: Oral Chemotherapy

Results of an ongoing open-label, phase II study of carfilzomib in patients with relapsed and/or refractory multiple myeloma (R/R MM)

PX-171–004, a multicenter phase II study of carfilzomib (CFZ) in patients with relapsed myeloma: An efficacy update

The effect of carfilzomib (CFZ) in patients (Pts) with bortezomib (BTZ)-naive relapsed or refractory multiple myeloma (MM): Updated results from the PX-171-004 study

PX-171-003-A1, an open-label, single-arm, phase (Ph) II study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (R/R MM): Long-term follow-up and subgroup analysis

Efficacy of induction with cybord in newly diagnosed multiple myeloma

A333 Phase I/II Trial of Cyclophosphamide, Prednisone, and Lenalidomide for Relapsed and Refractory MM

Suchergebnisse filtern